CA
BSTC

Calton & Associates’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Calton & Associates’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-75
Closed -$3K – 1409
2017
Q4 		$3K Buy
+75
New +$3.37K ﹤0.01% 1370

Other funds holding BSTC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Calton & Associates's BSTC Position: Q1 2018 in Review

Calton & Associates sold out of BioSpecifics Technologies Corp. (BSTC) in Q1 2018, closing a stake of 75 shares — an estimated $3K sold.

Calton & Associates first reported a position in BSTC in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 78 funds tracked by Wall St. Rank hold BSTC as of Q1 2018.

  • Calton & Associates reported no remaining BioSpecifics Technologies Corp. position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 75 BioSpecifics Technologies Corp. shares in Q1 2018, an estimated $3K.
  • Calton & Associates first reported a position in BioSpecifics Technologies Corp. in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's BioSpecifics Technologies Corp. position peaked at $3K in Q4 2017.
  • 78 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.